D. Boral Capital Reiterates Buy Rating for Hoth Therapeutics (NASDAQ:HOTH)

Hoth Therapeutics (NASDAQ:HOTH)‘s stock had its “buy” rating restated by investment analysts at D. Boral Capital in a note issued to investors on Tuesday,Benzinga reports. They currently have a $5.00 price objective on the stock. D. Boral Capital’s price target points to a potential upside of 362.96% from the company’s current price.

Separately, HC Wainwright reissued a “buy” rating and set a $4.00 target price on shares of Hoth Therapeutics in a report on Thursday, January 23rd.

Hoth Therapeutics Stock Performance

HOTH stock opened at $1.08 on Tuesday. Hoth Therapeutics has a fifty-two week low of $0.58 and a fifty-two week high of $3.80. The stock has a fifty day moving average of $1.13 and a 200-day moving average of $0.94. The company has a market capitalization of $7.45 million, a price-to-earnings ratio of -0.82 and a beta of 0.80.

Hoth Therapeutics (NASDAQ:HOTH) last issued its earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.01). Equities analysts predict that Hoth Therapeutics will post -1.36 EPS for the current year.

Hedge Funds Weigh In On Hoth Therapeutics

A hedge fund recently bought a new stake in Hoth Therapeutics stock. Virtu Financial LLC purchased a new position in Hoth Therapeutics, Inc. (NASDAQ:HOTH) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 32,636 shares of the company’s stock, valued at approximately $29,000. Virtu Financial LLC owned 0.47% of Hoth Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 7.08% of the company’s stock.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.